



**Name: Serge, Muyltermans**

**Email: [svmuylde@vub.ac.be](mailto:svmuylde@vub.ac.be)**

**Phone: +32-2-629.1969**

**Fax: +32-2-629.1981**

Dr Serge Muyltermans obtained his PhD at the Vrije Universiteit Brussel in 1982 and is currently heading the laboratory of 'Cellular and Molecular Immunology' at the same university. This laboratory is part of the VIB (Vlaams Interuniversitair Instituut voor Biotechnologie) department of 'Structural Biology'. Within this department he developed the technology to select Nanobodies, the antigen-binding fragment (single domain) of camel-specific Heavy-chain antibodies that were discovered at the university of Brussels in 1993. The Nanobody selection technology is a proven approach whereby over 600 Nbs against more than 100 targets have been identified in the past few years. These nanobodies are employed in numerous applications in medical and research fields. The research group is/has been involved in several international programs (bilateral programs, NATO, NHGRI, USDA & EU) and performs contract research for major industrial partners. His group published more than 100 articles (of which ~15 in journals with Impact Factor >10), and co-founded the spin-off company Ablynx that counts currently some 280 employees. Ablynx aims at utilising their Nanobodies as therapeutics to treat various human diseases.

#### **Publications Related to Camelid (Last ten years)**

1. Flajnik M, Deschacht N, **Muyltermans S (2011)**. Unsolved mystery: Convergent evolution of shark and camel and shark heavy-chain only antibodies. *PLoS Biology*, **9** (8), e1001120, doi:10.1371/journal.pbio.1001120, August, 2011 (IF = 13).
2. Stijlemans B, Conrath K, Perez-Morga D, Saerens D, Brys L, Nolan D, De Baetselier P, Pays E, Magez S, and **Muyltermans S. (2011)**. Complement-independent lysis of *Trypanosoma brucei brucei* with camel single domain antibody fragment. *PLoS Pathogens*, **7** (6), e1002072, 2011 (IF = 9.079)
3. Abbady AQ, Al-Marir A, Zarkawi M, Al Assad A, **Muyltermans S. (2011)**. Evaluation of nanobody phage display library constructed from Brucella-immunized camel Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. *Veterinary Immunology and Immunopathology*, **142**, 49-52, 2011 (IF = 2.176)
4. Smolarek D., Hattab C., Hassanzadeh-Ghassabeh,G., Cochet S., Gutiérrez C., de Brevern A., Udomsangpetch R., Picot J., Grodecka M., Wasniowska K., **Muyltermans S.** Colin Y., Le-Van-Kim C., Czerwinski M., and Bertrand O. (2010). A recombinant dromedary antibody fragment (VHH) directed against human Duffy Antigen Receptor for Chemokines. *Mol Cell Life Sci* **67**, 3371-

3387, 2010 (IF 5).

5. Hmila I., Saerens D., Ben-Abderrazek R., Vincke C., Abidi N., Benlasfar Z., Dabbek H., El Ayeb M., Bouhaouala-Zahar B., **Muyldermans S. (2010)**. Effective neutralisation of whole scorpion venom by a bispecific Nanobody. *FASEB J.* **24**, 3479-3489, 2010 (IF>5)
6. Deschacht N., De Groeve K., Vincke C., Raes G., De Baetselier P., **Muyldermans S. (2010)**. A promiscuous class of camelid single domain antibody contributes to the antigen-binding repertoire. *J. Immunol.* **184**, 5696-5704, 2010 (IF>5)
7. **Muyldermans S. (2009)**. Camel antibodies in medicine and biotechnology. Chapter in book: "It takes two-2 to do science" VUB Press edited by H. Eisendrath & JP Van Bendegem ISBN 978 90 5487 6052
8. **Muyldermans S.**, Baral TN., Cortez-Retamozo V., De Baetselier P., De Genst E., Kinne J., Leonhardt, Magez S., Nguyen VK., Revets H., Rothbauer U., Stijlemans B., Tillib S., Wernery U., Wyns L., Hassanzadeh Ghassabeh Gh, Saerens D. **(2009)**. *Camelid immunoglobulins and nanobody technology*.
9. *Veterinary Immunology and Immunopathology.* **128**, 178-183, 2009 (IF ~2.5).
10. Chan PH., Pardon E., Menzer L., De Genst E., Kumita JR., Christodoulou J., Saerens D., Brans A., Bouillenne F., Archer D., Robinson CV., **Muyldermans S. (2008)**. Matagne A., Redfield C., Wyns L., Dobson CM., Dumoulin M. *Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils*. *Biochemistry*, **47**, 11041-11054, 2008 (IF ~4).
11. Vincke C., Pellis M., Baral TN., Stijlemans B., Tillib S., Rothbauer U., Leonhardt H., Conrath K., Magez S., Wernery U., De Baetselier P., **Muyldermans S. (2008)**. *Camel antibodies for therapeutic and research applications*. *J. Camel Practice and Research Proceedings of the international camel conference*. 71-75, 2008. (IF ~0.1).
12. Saerens D., Pellis M., Vincke C., Pardon E., Conrath K., **Muyldermans S. (2006)** Contribution of camelids in functional genomics. *Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine* (Ed. K. Ruckpaul & D. Ganten) Springer-Verlag GmbH & Co. KG Berlin Heidelberg., ISBN: 3-540-44244-8
13. Kacs Kovics I, Mayer B, Kis Z, Frenyo L, Zhao Y, **Muyldermans S**, Hammarström L. **(2006)** Cloning and characterization of the dromedary (*Camelus dromedarius*) neonatal Fc receptor (drFcRn). *Dev. Comp. Immunol.* **30**, 1203-1215.
14. Baral T.N., Magez S., Stijlemans B., Conrath K., Vanhollebeke B., Pays E., **Muyldermans S.**, and De Baetselier P. **(2006)** African trypanosomiasis therapy with nanobody conjugated human trypanolytic factor. *Nature Med.*,

12, 580-584.

15. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, **Muyldermans S**, and Wyns L. (2006) Molecular basis for the unique epitope specificity of camelid heavy-chain antibodies. *Proc.Natl.Acad.Sci.*, 103, 4586-4591.
16. Marquardt A., **Muyldermans S.**, Przybylski M. (2006). A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high resolution affinity-mass spectrometry. *Chemistry – A European Journal*, 12, 1915-1923.
17. De Genst E, D. Saerens, **Muyldermans S**, and Conrath K. (2006). Antibody repertoire development in camelids. *Dev. Comp. Immunol.* 30, 187-198.
18. Saerens D., Frederix F., Reekmans G., Conrath K., Jans K., Brys L., Huang L., Bosmans E., Maes G., Borghs G., **Muyldermans S.** (2005) Engineering camel Single domain antibodies and immobilisation chemistry for human Prostate-Specific Antigen Sensing. *Anal. Chem.* 77, 7547-7555.
19. Zou X, Smith JA, Nguyen VK, Ren L, Luyten K, **Muyldemans S**, and Brüggemann M. (2005). Expression of a dromedary Heavychain-only antibody and B-cell development in the mouse. *J. Immunol.* 175, 3769-3779.
20. Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A, Wyns L, **Muyldermans S**, and Conrath K. (2005). Identification of a universal framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. *J.Mol.Biol.* 352, 597-607.
21. Huang L, Reekmans G, Saerens D, Friedt JM, Frederix F, Francis L, **Muyldermans S**, Campitelli A, and Van Hoof C. (2005). Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. *Biosensors and Bioelectronics*, 21, 483-490.
22. Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, **Muyldermans S**, and Loris R. (2005). Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. *J.Mol.Biol* 350, 112-125.
23. De Genst E., Handelberg F., Van Meirhaeghe A., Vinck S., Loris R., Wyns L., **Muyldermans S.** (2004). Chemical basis for the affinity maturation of a camel single domain antibody. *J Biol Chem.* 279, 53593-53601.
24. Saerens D, Kinne J, Bosmans E., Wernery U., **Muyldermans S.**, Conrath K. (2004). Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. *J Biol Chem*, 279, 51965-51972.
25. Pleschberger M., Saerens D., Weigert S., Sleytr U.B., **Muyldermans S.**, Sara M., Egelseer E.M. (2004). An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-

- specific antigen by surface plasmon resonance technology. *Bioconj. Chem.* **15**, 664-671.
26. Dumoulin M., A.M. Last, A. Desmyter, K. Decanniere, D. Canet, G. Larsson, A. Spencer, D.B. Archer, J. Sasse, **S. Muyldermans**, L. Wyns, C. Redfield, A. Matagne, C.V. Robinson, C.M. Dobson. (2003). A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. *Nature*, **424**, 783-788.
  27. V.K. Nguyen, X. Zou, M. Lauwereys, L. Brys, M. Bruggemann & **S. Muyldermans**. (2003). Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B-cells. *Immunology* **109**, 93-101.
  28. M. Pleschberger, A. Neubauer, E.M. Egelseer, S. Weigert, B. Lindner, U.B. Sleytr, **S. Muyldermans** & M. Sara. (2003). Generation of a functional monomolecular protein lattice consisting of an S-layer fusion protein comprising the variable domain of a camel heavy chain antibody. *Bioconjugate Chemistry* **14**, 440-448.
  29. K.E. Conrath, U. Wernery, **S. Muyldermans** & V.K. Nguyen (2003). Emergence and evolution of functional heavy-chain antibodies in Camelidae. *Developmental and Comparative Immunology* **27**, 87-103.
  30. Desmyter A., S. Spinelli, F. Payan, M. Lauwereys, L. Wyns, **S. Muyldermans** & C. Cambillau. (2002). Three camelid VHH domains in complex with porcine pancreatic  $\alpha$ -amylase: inhibition and versatility of binding topology. *J. Biol. Chem.* **277**, 23645-23650.
  31. V.K. Nguyen, C. Su, **S. Muyldermans** & W. van der Loo. (2002). Heavy chain antibodies in Camelidae, a case of evolutionary innovation. *Immunogenetics* **54**, 39-47.
  32. V. Cortez-Retamozo, M. Lauwereys, Gh.Gh. Hassanzadeh, M. Gobert, K. Conrath, **S. Muyldermans**, P. De Baetselier, H. Revets. (2002). Efficient tumor targeting by single-domain antibody fragments of camels. *International Journal of Cancer* **89**, 456-462.